Not Disclosed

About AbBC Therapies

AbBC Therapies is a private, preclinical-stage biotech based in Cambridge, USA, founded in 2020. The company is developing a novel class of antibody biologics that combine antibody targeting with the natural apoptotic enzyme Granzyme B, aiming to overcome limitations of traditional ADCs and checkpoint inhibitors. Its platform is designed to be fully biologic, potentially offering improved safety, efficacy, and manufacturing scalability. The company has a pipeline of seven active programs in oncology and ophthalmology, with two in IND-enabling stages.

About MAA Laboratories

MAA Laboratories is a private, pre-revenue biotech company leveraging its proprietary NanoCont™ platform to reformulate existing drug molecules into next-generation therapies. The platform combines nanoparticle engineering with continuous manufacturing to enhance drug performance across multiple therapeutic areas, with a pipeline strategy focused on streamlined 505(b)(2) regulatory pathways. Led by an experienced team with deep pharmaceutical development and regulatory expertise, the company is advancing multiple programs with FDA-reviewed clinical strategies and is actively seeking partnerships to commercialize its technology.

About Apriori Bio

Apriori Bio is a Flagship Pioneering-founded biotech based in Cambridge, MA, established to transform vaccinology through predictive biology and AI. Its core technology, the Octavia platform, experimentally maps viral fitness landscapes to anticipate evolutionary pathways, enabling the design of vaccine antigens intended to elicit broader and more potent immune responses against both existing and future strains. The company is in a pre-clinical stage, building its pipeline against seasonal and pandemic respiratory viruses, and is led by a team with deep expertise in biotechnology, vaccinology, and computational science. Its strategy hinges on validating its predictive platform to create next-generation vaccines that could offer more durable and universal protection.

About Tessel Biosciences

Tessel Biosciences is a private, pre-clinical stage biotech based in Boston, combining a 'virtual tissues' platform with AI to design real drugs. The company is developing a pipeline targeting the causes and consequences of tissue remodeling, starting with lung diseases, by using its proprietary Tesselogic platform to run optimized experiments on patient-derived tissues. Led by a technically strong team with backgrounds from MIT, Harvard, and top AI/drug discovery firms, Tessel appears to be pre-revenue and focused on platform validation and early pipeline advancement. Its approach aims to bridge the gap between complex human biology and scalable, causal drug discovery.

About EndObetes

EndObetes is a private, preclinical-stage biotech targeting the vast and growing diabetes and metabolic disease market. As a pre-revenue entity, it is likely backed by venture capital and is in the research-intensive phase of developing its proprietary platform and lead candidates. The company's success hinges on translating its novel science into clinically validated therapies that can differentiate in a competitive but high-need therapeutic landscape.

About Duo Oncology

Duo Oncology is a private, preclinical-stage biotech founded in 2020, headquartered in Cambridge, MA. The company is developing a proprietary nanomedicine platform that mimics DNA self-assembly to create exceptionally small particles capable of deep tumor penetration and environmentally triggered drug release. Led by an experienced team of oncologists and pharmaceutical scientists, Duo is building a pipeline of combination therapies targeting high-unmet-need cancers, supported by non-dilutive funding like an NCI STTR grant. Its core value proposition is overcoming stromal barriers to deliver potent drug combinations precisely where needed.

About ONK Therapeutics

ONK Therapeutics is a private, preclinical-stage biotech based in Galway, Ireland, pioneering an engineered NK cell therapy platform. The company's core strategy involves genetic modifications, including a foundational CISH knockout, to enhance the potency, homing, and durability of off-the-shelf NK cells. While still in preclinical development, ONK is actively forming research partnerships to advance its pipeline and platform, targeting a significant opportunity in both hematological malignancies and solid tumors.

Therapeutic Areas